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Abstract
The Whi5 transcriptional repressor is a negative regulator of G1 cell cycle progression in Saccharomyces cerevisiae and is
functionally equivalent to the Retinoblastoma (Rb) tumor suppressor protein in mammals. In early G1, Whi5 binds to and
inhibits SBF (Swi4/Swi6) transcriptional complexes. At Start, Cln:Cdc28 kinases phosphorylate and inactivate Whi5, causing
its dissociation from SBF promoters and nuclear export, allowing activation of SBF transcription and entry into late G1. In an
analysis of Whi5 phosphorylation, we found that 10 of the 12 putative CDK phosphorylation sites on Whi5 were occupied in
vivo in asynchronously growing cells. In addition, we identified 6 non-CDK Whi5 phosphorylation sites. Whi5 CDK and non-
CDK phosphorylation mutants were functional and able to rescue the small cell size of whi5D cells. However, the Whi5 CDK
mutant with all 12 putative CDK sites changed to alanine causes a dramatic cell cycle phenotype when expressed with a
Swi6 CDK phosphorylation mutant. Mutational analysis of Whi5 determined that only four C-terminal CDK sites were
necessary and sufficient for Whi5 inactivation when Swi6 CDK sites were also mutated. Although these four Whi5 CDK sites
do not wholly determine Whi5 nuclear export, they do impact regulation of cell size. Taken together, these observations
begin to dissect the regulatory role of specific phosphorylation sites on Whi5.
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Introduction
Cell proliferation is a tightly regulated process where extracel-
lular signals and intracellular checkpoints are integrated to control
cell growth and division. When conditions for cell division are
favorable, cells commit to enter the cell cycle during G1 phase at
an irreversible transition termed Start in yeast and the Restriction
Point in mammalian cells [1,2]. In yeast, environmental nutrient
availability regulates accumulation of cellular mass to a critical cell
size before Start [3]. In mammalian cells, growth factor signaling
determines passage through the Restriction Point that is also
presumed to be partially responsive to cell size and mass. Failure to
properly regulate cell cycle entry can result in abnormal division
and lead to development of neoplastic disease [4]. The molecular
events determining commitment to cell division in both yeast and
mammalian cells involve regulated transcription of groups of genes
required for cell cycle progression [5,6]. In yeast, expression of
genes at Start depends on SBF and MBF transcription factor
complexes; each consists of the transcriptional coactivator Swi6
and a DNA binding protein, Swi4 or Mbp1, respectively [1]. In
general, SBF controls transcription of cell cycle regulatory genes,
while genes involved in DNA synthesis and repair are MBF targets
[7]. Loss of both Swi4 and Mbp1 results in a permanent G1 arrest
and cell lethality, demonstrating the essential function of these
transcription factor complexes [8].
In early G1, SBF complexes bind target promoters, but due to
binding by the Whi5 transcriptional repressor, do not initiate
transcription until Start [9,10]. The cyclin Cln3 is an activator of
cellcycle progression and ensures proper timing of transcription once
cells reach a critical cell size [11,12]. Cells lacking CLN3 have a large
cell size phenotype and are delayed in transcriptional activation and
passage through Start [11–13]. Whi5 is a key target of Cln3-Cdc28
cyclin dependent kinase (CDK) in transcriptional activation of SBF.
Phosphorylation of Whi5 and SBF complexes by Cln3-Cdc28 results
in Whi5 dissociation from SBF promoters and nuclear export,
allowingforinductionofSBFtranscriptionandcellcycleentry[9,10].
Consequently, cells lacking WHI5 initiate SBF transcription
prematurely, driving cells past Start and resulting in a small cell
size [14]. In addition to Whi5, Swi4 and Swi6 are also known targets
of CDK phosphorylation and genetic studies implicate Swi6 as a
critical target of Cln3 [15]. However, mutation of CDK phosphor-
ylation sites of Swi4 or Swi6 does not interfere with timing of SBF
transcription [15–17]. Interestingly, a Whi5 CDK phosphorylation
mutant causes cell lethality when expressed in a Swi6 CDK
phosphorylation mutant background, suggesting that CDK phos-
phorylation of Whi5 and Swi6 is redundant for transcriptional
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During the late G1 to early S-phase transition, Swi6 is phosphor-
ylated by cyclin Clb6-Cdc28 on Ser-160, changing Swi6 cellular
localization from nuclear to cytoplasmic [16,18]. This serves to
inactivate SBF transcription outside of G1. It is not currently known
what mechanisms repress MBF in early G1 or activate MBF at Start,
although the MBF target Nrm1 is responsible for repression of MBF
upon exit from G1 [19].
A functionally similar system of transcriptional regulation occurs
in mammalian cells. The E2F family of transcription factors
control expression of a suite of E2F target genes essential for late
G1 cell cycle progression and DNA synthesis [20]. In early G1,
E2Fs are bound and repressed by the Retinoblastoma Tumor
Suppressor protein (Rb), a functional analogue of Whi5 [21,22].
At the restriction point, activation of Cyclin E-Cdk2 kinase
complexes results in Rb hyper-phosphorylation and inactivation,
allowing for cell cycle-dependent E2F transcription [23]. Studies of
Rb regulation by phosphorylation show Rb is phosphorylated at
low levels, or hypo-phosphorylated, when bound to E2Fs in early
G1 [24]. Additionally, it has been proposed by some groups that
specific CDK sites on Rb are utilized for inactivation [25,26],
while others suggest a model where a critical threshold of
phosphorylation on any of Rb’s 16 CDK sites induces inactivation
[27,28]. However, the mechanistic understanding of Rb regulation
by phosphorylation remains unclear.
Due to the conserved regulatory pathways controlling G1
transcription between yeast and mammalian cells, investigation of
regulation by phosphorylation of Whi5 in yeast could provide
insight into mammalian G1 cell cycle and Rb regulation. In an
analysis of Whi5 phosphorylation, we determined that Whi5 is also
found hypo-phosphorylated in early G1, but that hypo-phosphor-
ylation is not required for Whi5 function. Additionally, we identify
four specific CDK sites in Whi5 that are critical for Whi5
inactivation and the regulation of cell size when Swi6 phosphor-
ylation is also prevented. These results demonstrate that regulation
of Whi5 by phosphorylation relies on specific CDK sites.
Materials and Methods
Yeast Culture and Strains
Cells were grown in standard media containing yeast extract,
peptone, and 2% glucose. For induction experiments, cells were
grown overnight in media containing 2% raffinose then inoculated
into 2% galactose media or galactose plates. A 13x-Myc tag was
appended to WHI5 using the method of Longtine et al [29]. The
WHI5 promoter construct derived from 545 base pairs 59 of the
WHI5 open reading frame was PCR amplified from genomic
DNA and cloned into the pRS413 vector [30].
See Table 1 for a list of yeast strains used in this study.
Protein Purification
Cells expressing GAL1-WHI5-3xHA or GAL1-WHI5-12Ala-3xHA
were grown in raffinose then induced with galactose for ten hours.
Cells from twelve liters of culture were harvested by centrifugation
and drop frozeninliquid nitrogen. Cells were brokenwith a Waring
blender in liquid nitrogen. Resulting powder was resuspended in
RIPA buffer with protease and phosphatase inhibitors. Cells debris
was pelleted by high-speed centrifugation. Immunoprecipitation
with HA affinity resin (Roche) was performed overnight. Immuno-
precipitates were washed and boiled in SDS-sample buffer then
resuspended in RIPA buffer, diluting the SDS to 1%, before a
second immunoprecipitation was performed. Samples from the
double immunoprecipitation were separated by 10% SDS-PAGE
and stained with Coomassie blue.
Mass Spectrometry
After in-gel digestion, phosphopeptides were purified by IMAC
as previously described [31]. Purified phosphopeptides were
analyzed by mLC-ESI-MS/MS on a Thermo Finnigan LTQ
quadrupole ion trap mass spectrometer as described [31]. For data
analysis, SEQUEST (version 3.4 beta 2) program running on a
Sorcerer system (SageN, San Jose, CA) was used for peptide
identification. Database search was performed using the budding
yeast database. The following variable modifications were
considered: +80 Da (phosphorylation) for serine, threonine and
tyrosine residues; +16 Da (oxidation) for methionine residues. Up
to 4 variable modifications were allowed per peptide and peptide
mass tolerance used was 3 Da. A semi-tryptic restriction was
applied, and only the top-matched peptides with a probability
score above 0.9 were subsequently considered for close inspection.
Each MS/MS spectrum that led to phosphopeptide identification
was manually verified to confirm all significant ions were
accounted for, and then validated.
Protein Analysis and Phosphatase Treatment
Cells were broken with glass beads in 50 mM Tris, pH 8,
150 mM NaCl, 2 mM EDTA, 10% glycerol, 0.2% NP-40 lysis
buffer containing protease (PMSF, aprotinin, leupeptin, benzami-
dine) and phosphatase inhibitors (Sigma cocktails 1 and 2).
Immunoprecipitation was performed with anti-Myc antibody
(Santa Cruz) and protein G beads (Zymed) or anti-HA conjugated
beads (Roche). After washing with lysis buffer without phosphatase
inhibitors, and 50 mM Tris, pH 8, 50 mg/mL BSA, 25 uM DTT
buffer, immunoprecipitates were incubated with lambda protein
phosphatase (New England Biolabs) in supplied buffer for 1 hour
at 30 degrees [32]. Analysis of protein migration utilized 10%
SDS-PAGE run for 10–12 cm.
Cell Size Measurements
Cell size analysis was performed on asynchronous cultures
during log-phase growth using a Coulter Z2 Particle Cell Analyzer
(Beckman-Coulter). Cultures were briefly sonicated before analy-
sis. Cell size distribution was analyzed with the Z2 AccuComp
software (Beckman-Coulter).
Microscopy
Fluorescence and differential interference contrast microscopy
was performed on live cells with a DeltaVision RT Microscope
(Applied Precision Life Science) using a 1006oil objective. Image
processing was done with ImageJ software and fluorescent and
DIC images were overlaid using Adobe Photoshop.
Cell Synchronization
Cells in log phase growth were washed, resuspended in fresh
media containing 5 mg/mL alpha factor (Sigma), and incubated
for three hours at 30 degrees. To release, cells were washed twice
with cold media then inoculated into warm media. At indicated
time points, samples were taken, cooled with ice, sonicated, then
analyzed for budding index.
Results
Whi5 is phosphorylated on 16 CDK and non-CDK sites in
vivo
Whi5 contains 12 putative CDK phosphorylation sites typified
by S/T-P(-X-B) and phosphorylation by Cln:Cdk activity has been
shown to be important in Whi5 inactivation [9,10]. de Bruin et al.
had previously determined that CDK sites 2, 4, 5, 10 and 12 were
Whi5 Phosphorylation
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identify Whi5 phosphorylation sites in vivo in a comprehensive
manner, we performed mass spectrometry analysis of Whi5. Wild
type Whi5 containing a 36HA C-terminal tag under the control
of the GAL1 promoter was immunopurified from asynchronously
growing cells, digested with trypsin, and phosphopeptides were
purified by IMAC resin liquid chromatography enrichment then
analyzed by mass spectrometry. Ten of the 12 putative Whi5
CDK phosphorylation sites, numbered 3–12, were identified as
being phosphorylated in asynchronous cells (Fig. 1), while
phosphorylation of sites 1 and 2 were not detected by our
methods. Because de Bruin et al. verified phosphorylation of CDK
site 2 [10], and it is possible CDK site 1 is phosphorylated but not
detected by our methods, we utilize a Whi5-12Ala phosphoryla-
tion mutant in our following studies. Surprisingly, in addition to
CDK sites, we also identified 6 other non-CDK serine and
threonine residues phosphorylated on Whi5, labeled A to F (Fig. 1).
We note that 5 of the 6 non-CDK phosphorylation sites contain an
acidic residue distal to the phosphorylated S/T. Mass spectrom-
etry analysis of 36HA C-terminal tagged mutant Whi5 with all 12
CDK sites changed to alanine (Whi5-12Ala-3xHA) maintained
phosphorylation of these 6 non-CDK sites. In total, we identified
16 phosphorylation sites on Whi5 in asynchronously growing cells.
Whi5 is phosphorylated at all stages of the cell cycle
We next analyzed the cell cycle dependency of Whi5
phosphorylation, utilizing a strain containing a C-terminal 3x-
Myc tag integrated at the WHI5 locus. In lysates from
asynchronously growing cells, Whi5-13xMyc protein migrates as
Table 1.
Yeast
Strain Genotype Source
MWY01 BY4741 his3D met3D ura3D leu2D Brachmann et al.
MWY02 WHI5-13xMyc::kanMX6 This study
MWY03 [pRS413 GAL1-WHI5-3xHA] This study
MWY04 [pRS413 GAL1-WHI5-12Ala-3xHA] This study
MWY05 [pRS413 GAL1-WHI5-13xMyc] This study
MWY05 [pRS413 GAL1-WHI5-12Ala-13xMyc] This study
MWY06 [pRS413 GAL1-WHI5-6Ala-13xMyc] This study
MWY07 [pRS413 GAL1-WHI5-18Ala-13xMyc] This study
MWY08 whi5D::kanMX6 deletion collection
MWY09 whi5D::kanMX6 [pRS413 545pr-WHI5] This study
MWY10 whi5D::kanMX6 [pRS413 545pr-WHI5-12Ala] This study
MWY11 whi5D::kanMX6 [pRS413 MET3-WHI5] This study
MWY12 whi5D::kanMX6 [pRS413 MET3-WHI5-12Ala] This study
MWY13 whi5D::kanMX6 [pRS413 MET3-WHI5-6Ala] This study
MWY14 whi5D::kanMX6 [pRS413 MET3-WHI5-18Ala] This study
MWY15 [pRS413] Brachmann et al.
MWY16 [pRS413 GAL1-WHI5] Costanzo et al.
MWY17 [pRS413 GAL1-WHI5-12Ala] Costanzo et al.
MWY18 [pRS413 GAL1-WHI5-6Ala] This study
MWY19 [pRS413 GAL1-WHI5-18Ala] This study
MWY20 cln3D::kanMX6 [pRS413] deletion collection
MWY21 cln3D::kanMX6 [pRS413 GAL1-WHI5] This study
MWY22 cln3D::kanMX6 [pRS413 GAL1-WHI5-12Ala] This study
MWY23 cln3D::kanMX6 [pRS413 GAL1-WHI5-6Ala] This study
MWY24 cln3D::kanMX6 [pRS413 GAL1-WHI5-18Ala] This study
MWY25 swi6D::kanMX6 [yEp SWI6-SA4] Breeden et al.
MWY26 MWY25 [pRS413] This study
MWY27 MWY25 [pRS413 GAL1-WHI5] This study
MWY28 MWY25 [pRS413 GAL1-WHI5-12Ala] This study
MWY29 MWY25 [pRS413 GAL1-WHI5-6Ala] This study
MWY30 MWY25 [pRS413 GAL1-WHI5-18Ala] This study
MWY31 MWY25 [pRS413 GAL1-WHI5-7Ala] deBruin et al.
MWY32 MWY25 [pRS413 GAL1-WHI5-4Ala] This study
MWY33 MWY25 [pRS413 GAL1-WHI5-8Ala
1] This study
MWY34 MWY25 [pRS413 GAL1-WHI5-8Ala
2] This study
MWY35 MWY25 [pRS413 GAL1-WHI5-1Ala
1] This study
MWY36 MWY25 [pRS413 GAL1-WHI5-1Ala
2] This study
MWY37 MWY25 [pRS413 GAL1-WHI5-2Ala
1] This study
MWY38 MWY25 [pRS413 GAL1-WHI5-2Ala
2] This study
MWY39 MWY25 [pRS413 GAL1-WHI5-11Ala
1] This study
MWY40 MWY25 [pRS413 GAL1-WHI5-11Ala
2] This study
MWY41 MWY25 [pRS413 GAL1-WHI5-10Ala
1] This study
MWY42 MWY25 [pRS413 GAL1-WHI5-10Ala
2] This study
MWY43 MWY25 [pRS413 GAL1-WHI5-9Ala
1] This study
MWY44 MWY25 [pRS413 GAL1-WHI5-9Ala
2] This study
MWY45 MWY25 [pRS413 GAL1-WHI5-3Ala
1] This study
MWY46 MWY25 [pRS413 GAL1-WHI5-6Ala
1] This study
MWY47 MWY25 [pRS413 GAL1-WHI5-3Ala
2] This study
MWY48 MWY25 [pRS413 GAL1-WHI5-6Ala
2] This study
Yeast
Strain Genotype Source
MWY49 [pRS413 GAL1-WHI5-GFP] This study
MWY50 [pRS413 GAL1-WHI5-12Ala-GFP] This study
MWY51 [pRS413 GAL1-WHI5-4Ala-GFP] This study
MWY52 [pRS413 GAL1-WHI5-8Ala
1-GFP] This study
MWY53 msn5D::kanMX6 [pRS413 GAL1-WHI5-GFP] This study
MWY54 msn5D::kanMX6 [pRS413 GAL1-WHI5-13xMyc] This study
MWY55 swi6D::kanMX6 [pRS413 GAL1-WHI5-GFP] This study
MWY56 swi6D::kanMX6 [pRS413 GAL1-WHI5-13xMyc] This study
MWY57 GAL1-MSN5 [pRS413 GAL1-WHI5-GFP] This study
MWY58 GAL1-MSN5 [pRS413 GAL1-WHI5-12Ala-GFP] This study
MWY59 swi6D::kanMX6 deletion collection
MWY60 swi6D::kanMX6 whi5D::URA3 This study
MWY61 MWY60 [yEp SWI6] [pRS413 545pr-WHI5] This study
MWY62 MWY60 [yEp SWI6] [pRS413 545pr-WHI5-12Ala] This study
MWY63 MWY60 [yEp SWI6-SA4] [pRS413 545pr-WHI5] This study
MWY64 MWY60 [yEp SWI6-SA4] [pRS413
545pr-WHI5-12Ala]
This study
MWY65 MWY60 [yEp SWI6] [pRS413 545pr-WHI5-4Ala] This study
MWY66 MWY60 [yEp SWI6] [pRS413 545pr-WHI5-8Ala
1] This study
MWY67 MWY60 [yEp SWI6-SA4] [pRS413
545pr-WHI5-4Ala]
This study
MWY68 MWY60 [yEp SWI6-SA4] [pRS413
545pr-WHI5-8Ala
1]
This study
doi:10.1371/journal.pone.0004300.t001
Table 1. cont
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mating pheromone, where CDK activity is inhibited by Far1
[33,34], Whi5-13xMyc migrates as a single, faster migrating band.
In contrast, in cells arrested in M phase by nocodazole, where
CDK activity is high, the slower migrating species was enriched.
To test whether the difference in migration of the Whi5 bands was
due to phosphorylation, immunoprecipitates of Whi5-13xMyc
were treated with lambda phosphatase (Fig. 2B). Upon phospha-
tase treatment, both the slower and faster migrating species of
Whi5 from asynchronous cells collapsed into a third, fastest
migrating un-phosphorylated band. Phosphatase treatment of
Whi5-13xMyc from mating pheromone and nocodazole-arrested
cells both induced appearance of the un-phosphorylated band.
Thus, Whi5 can be separated into three species: the slowest
migrating form of Whi5, designated hyper-phosphorylated; the
middle form, designated hypo-phosphorylated; and the fastest
form, designated un-phosphorylated. We note that the un-
phosphorylated form of Whi5 was not found at any cell cycle
stage or even in mating pheromone arrested cells. In addition, we
observe that Whi5 from mating pheromone arrested cells with
inhibited CDK activity shifted downward after phosphatase
treatment, suggesting the presence of non-CDK phosphorylation
events.
The phosphorylation status of Whi5 mutants was also analyzed
by phosphatase treatment. Wild type Whi5 or phosphorylation
mutants containing a C-terminal 13xMyc tag were expressed from
the GAL1 promoter on CEN plasmids. In samples of asynchro-
nous cells, mutation of the 6 non-CDK sites (A–F) to alanine did
not effect the migration of Whi5 compared to wild type Whi5
(Fig. 2C). Consistent with the mass spec analysis, mutation of
Whi5 CDK sites 1–12 to alanine resulted in a single hypo-
phosphorylated band that increased mobility after phosphatase
treatment. Since both Whi5-6Ala and Whi5-12Ala were found
phosphorylated, the non-CDK sites A–F are not essential for CDK
site phosphorylation, and vice versa. Finally, when all 12 CDK and
6 non-CDK sites were mutated to alanine in Whi5-18Ala,
migration did not change upon phosphatase treatment. In
addition, in vivo orthophosphate labeling verified that both Whi5-
6A and Whi5-12Ala are phosphorylated, although to a lesser
extent than wild type Whi5, while phosphorylation of Whi5-18Ala
was negligible (data not shown).
Functional Analysis of Whi5 phosphorylation mutants
whi5D cells exhibit a small cell size phenotype [14]. To assess the
functionality of Whi5 phosphorylation mutants, we assayed for
their ability to rescue whi5D small size (Fig. 3A). Wild type parent
strain BY4741 had a mean cell size distribution of 48.2 fL, while
the mean size of whi5D cells was 36.2 fL in this experiment.
Introduction of wild type WHI5 on a CEN plasmid under its
native promoter into whi5D cells rescues the small cell size defect
and returned the culture to a mean cell size of 53.2 fL. Expression
of WHI5-12Ala also rescued the small cell size phenotype, with a
mean cell size of 53.3 fL. Importantly, expression of WHI5-12Ala
from its own promoter did not result in a larger cell size than
WHI5-WT. This suggests CDK phosphorylation of Whi5 is not
essential for SBF activation or timing of Start, as loss of Whi5
CDK phosphorylation does not delay cell cycle progression.
Mutants in the non-CDK phosphorylation sites of Whi5 were also
assayed for ability to rescue whi5D cell size. In this experiment,
where cells are grown in synthetic media, parent strain BY4741
had a mean cell size of 35.3 fL, while whi5D cells were 31.5 fL.
Expression of WHI5 wild type, WHI5-12Ala (CDK), WHI5-6Ala
(non-CDK), or WHI5-18Ala (CDK and non-CDK) from the
inducible MET3 promoter on CEN plasmids was able to rescue
the small cell size of whi5D mutants, with mean cell sizes of 42.1,
43.5, 43.2 and 42.4 fL, respectively (Fig. 3B). We note that the
slightly larger cell size observed is likely due to constitutive
expression of Whi5 from the MET3 promoter, and was also
observed by de Bruin et al [10]. These observations indicate that
in wild type cells, phosphorylation of Whi5 on CDK sites or non-
Figure 1. Whi5 is phosphorylated on 16 sites in vivo. The primary amino acid sequence of Whi5 with putative CDK sites boxed in blue. Arrows
indicate amino acids found phosphorylated in vivo. Non-CDK sites phosphorylated in vivo are boxed in green.
doi:10.1371/journal.pone.0004300.g001
Whi5 Phosphorylation
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has previously been shown that Whi5 overexpression in cln3D cells
results in permanent cell cycle arrest in G1 prior to Start [9].
Similar to wild type Whi5, overexpression of Whi5-12Ala, Whi5-
6Ala, or Whi5-18Ala phosphorylation mutants from the GAL1
promoter on CEN plasmids caused lethality of cln3D cells (Fig. 3C),
suggesting that hypo-phosphorylation of either CDK or non-CDK
sites is not required for Whi5 to antagonize Cln3 activity.
Specific CDK phosphorylation sites of Whi5 are required
for function
Expression of variousWhi5 phosphorylationmutants in wild type
cells does not result in a dramatic phenotype [9,10]. However,
overexpression of Whi5-12Ala in cells that harbor the Swi6-SA4
mutant lacking four CDK sites results in a severe growth defect [9],
suggesting that phosphorylation of either Whi5 or Swi6 is required
for SBFactivation and cell cyclepromotion. To test if the non-CDK
sites of Whi5 are similarly essential for SBF activation in the
presence of Swi6-SA4, Whi5 mutants containing alanine substitu-
tions for the 6 non-CDK sites (Whi5-6Ala), and all CDK and non-
CDK sites (Whi5-18Ala) were tested in this assay. In cells expressing
wild type Swi6, all of the WHI5 constructs, WHI5-WT, WHI5-
12Ala, WHI5-6Ala,o rWHI5-18Ala expressed from the GAL1
promoter on CEN plasmids, showed no change in growth rate as
detected in this assay (data not shown). However, in combination
with SWI6-SA4, WHI5-12Ala and WHI5-18Ala cells were inviable,
whereas cells expressing WHI5-WT or WHI5-6Ala were viable
(Fig. 3D). Thus, phosphorylation of Whi5 non-CDK sites is not
necessary for SBF activation in a SWI6 or SWI6-SA4 genetic
background. We are currently unable to ascribe a biological
function for phosphorylation of Whi5 at the 6 non-CDK sites.
Although phosphorylation of multiple Whi5 CDK sites was
detected in vivo (Fig. 1 and de Bruin et al.) [10], it is not known
whether specific CDK sites or a threshold amount of phosphor-
ylation determines Whi5 inactivation and dissociation from SBF.
To test these two competing hypotheses of Whi5 inactivation, we
performed a mutational analysis of Whi5 CDK sites and assayed
for genetic interaction with the SWI6-SA4 allele (Fig. 4). Consistent
with previous reports [9], none of the Whi5 CDK mutants assayed
caused growth defects when induced in cells expressing wild type
Swi6 (data not shown). Similar to WHI5-12Ala, expression of
WHI5-7Ala (CDK sites 2, 3, 5, 8, 9, 10, and 12 mutated to alanine)
[10] caused lethality in combination with SWI6-SA4 (Fig. 4, lines 2
& 3). Based on a preliminary survey of phosphorylation site
mutants, we initially focused our attention on the C-terminal CDK
phosphorylation sites. Four C-terminal CDK sites of Whi5 (8, 9,
10, and 12) as a group were necessary and sufficient for viability
with Swi6-SA4. When WHI5-4Ala, with the four sites mutated to
alanine, is expressed in combination with SWI6-SA4, cells were
inviable (Fig. 4, line 4). In contrast, when WHI5-8Ala
1, where the
other 8 CDK sites in Whi5 are mutated to alanine, is expressed
with SWI6-SA4, cells were viable (Fig. 4, line 5). This demonstrates
that CDK sites 8, 9, 10, and 12 are specifically required for Whi5
inactivation in this assay. To rule out the possibility that
phosphorylation of any four CDK sites was sufficient to inactivate
Whi5, several constructs having four or more wild type CDK sites
were also analyzed. For example, when four N-terminal CDK sites
(2, 3, 4, and 5) are wild type while the other eight CDK sites are
alanine in WHI5-8Ala
2 (Fig. 4, line 6), the SWI6-SA4 cells were still
inviable, suggesting that the four N-terminal sites were not
sufficient to allow for viability.
Additional analysis of CDK sites 8, 9, 10, and 12 was performed
to assess their function as single sites, pairs of sites, or in groups of
Figure 2. Whi5 is phosphorylated throughout the cell cycle. (A) Cultures of strains expressing Whi5-13xMyc from the endogenous locus were
arrested in G1 phase with alpha factor or in metaphase with nocodazole. Western blot of Whi5-13xMyc shows two different migrating forms,
indicated by arrows. (B) Western blot of immunopurified Whi5-13xMyc treated with or without lambda phosphatase. Three different migrating forms
indicated by arrows represent unphosphorylated, hypo-phosphorylated, and hyper-phosphorylated Whi5. (C) Strains carrying CEN plasmids of
phosphorylation mutants of Whi5-13xMyc under the GAL1 promoter were grown in galatcose before immunopurification. Whi5-WT, non CDK mutant
6Ala, CDK mutant 12Ala, and CDK/non-CDK mutant 18Ala were treated with phosphatase as in B. Arrows indicate migration of three different
phosphorylation forms.
doi:10.1371/journal.pone.0004300.g002
Whi5 Phosphorylation
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or 8 and 9) to alanine, while leaving the other CDK sites wild type
did not affect cell growth (Fig. 4, lines 7–10). This demonstrates
that no single C-terminal CDK site or pair of sites is necessary for
viability. Conversely, mutating all other CDK sites to alanine,
leaving only single CDK sites 10 or 12, or pairs of sites (10 and 12;
Figure 3. Whi5 hypo-phosphorylation is not necessary for function. (A) Size analysis of whi5D cells with CEN plasmids expressing Whi5-WT
or Whi5-12Ala (CDK mutant) from the WHI5 promoter, a 545 bp fragment from sequence directly 59 of the WHI5 open reading frame. (B) Size analysis
of whi5D cells expressing Whi5-WT, Whi5-12Ala (CDK mutant), Whi5-6Ala (non CDK mutant), or Whi5-18A (CDK and non-CDK mutant) from the MET3
promoter on a CEN plasmid. (C) Wild type cells or cln3D cells with empty vector or CEN plasmid constructs of Whi5-WT, Whi5-12Ala, Whi5-6Ala, or
Whi5-18Ala under control of the GAL1 promoter. Cells were spotted in serial five fold dilutions on glucose or galactose media and incubated
48 hours. (D) swi6D [SWI6-SA4] cells bearing either empty vector or CEN plasmid constructs of Whi5-WT, Whi5-12Ala, Whi5-6Ala, or Whi5-18Ala under
the GAL1 promoter. Cells were spotted in serial five fold dilutions on glucose or galactose media and incubated 48 hours.
doi:10.1371/journal.pone.0004300.g003
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14). This indicates that phosphorylation of a single site or pair of
sites is not sufficient to support cell viability. Interestingly, when
three CDK sites (8, 9, and 12; or 8, 9, and 10) were left wild type,
they were sufficient to allow growth (Fig. 4, line 15), indicating 3
out of the 4 C-terminal CDK sites are sufficient for viability.
Because these mutants with only three functional CDK sites are
viable, the specific C-terminal CDK sites are adequate to promote
Whi5 inactivation. However, Whi5 regulation by phosphorylation
is complex in that some combinations of C-terminal mutations
with other CDK sites influenced viability (Fig. 4, lines 17 & 18,
lines 19 & 20). While CDK sites 8, 9, 10, and 12 are both
necessary and sufficient for viability in combination with Swi6-
SA4, supporting a model of specific sites utilized for inactivation,
other CDK sites are able to support inactivation in certain
combinations.
Localization of Whi5 CDK mutants
In wild type cells, Whi5 localization is nuclear in early G1, then
exported to the cytoplasm just prior to budding [9]. Since Swi6-
SA4 is constitutively localized in the nucleus [16], we hypothesized
that Whi5 CDK mutants that caused lethality with Swi6-SA4
might also have defects in nuclear export. Localization of GFP
tagged Whi5 was examined in wild type cells. As previously
reported [9], Whi5-WT-GFP is nuclear in unbudded cells and
cells just exiting mitosis, but is cytoplasmic in budded cells
(Fig. 5A). However, Whi5-12Ala-GFP was localized to the nucleus
in both unbudded and budded cells (Fig. 5B), confirming that
CDK phosphorylation is required for export [9]. The localization
of Whi5-4Ala-GFP, containing mutations of CDK sites 8, 9, 10,
and 12, is nuclear in unbudded cells (Fig. 5C), but is cytoplasmic in
only 16% of budded cells (Fig. 5C, 2
nd panel and Fig. 5E). Whi5-
8Ala
1-GFP, with CDK sites 8, 9, 10, and 12 wild type, is nuclear in
unbudded cells, and is cytoplasmic 35% of budded cells (Fig. 5D
and 5E). The localization of Whi5-WT-GFP and CDK mutants
was also examined in SWI6-SA4 cells, but was not different than
localization observed in wild type cells (Fig. 5E). These
observations suggest that in wild type or SWI6-SA4 cells, Whi5
C-terminal CDK sites 8, 9, 10, and 12 influence localization, but
are not entirely necessary or sufficient for wild type localization.
MSN5 is required for Whi5 nuclear export
Swi6 nuclear export is dependent on the karyopherin Msn5
[35]. Because Swi6 and Whi5 interact [9,10], we examined
whether Whi5 nuclear export was also Msn5 dependent. In msn5D
cells, GFP tagged Whi5-WT was constitutively nuclear, even in
budded cells (Fig. 6A). Whi5-WT was also nuclear in swi6D cells
(Fig. 6B), suggesting that Swi6 is also involved in Whi5 nuclear
export. Msn5 overexpression from the GAL1 promoter was not
sufficient to induce ectopic nuclear export of Whi5-WT, as its
localization remains nuclear in unbudded cells (Fig. 6C). Addi-
tionally, GAL1-MSN5 was unable to induce export of Whi5-12Ala
and localization remained constitutively nuclear (Fig. 6C). Simi-
larly, GAL1-MSN5 was unable to rescue the growth defect of
GAL1-WHI5-12A SWI6-SA4 co-expressing cells (data not shown).
Because Msn5 is known to export phosphoproteins [35–38], we
Figure 4. Mutational analysis of Whi5 phosphorylation sites. (A) swi6D [SWI6-SA4] cells expressing Whi5-WT or Whi5 phosphorylation
mutants from the GAL1 promoter. Cells were spotted in serial 5 fold dilutions on galactose media and incubated 48 hours. The table indicates the
CDK sites of Whi5 that were left wild type (S/T) or mutated to alanine (A) for each mutant construct. (B) Schematic of the Whi5 protein showing
relative location of CDK sites, numbered 1–12.
doi:10.1371/journal.pone.0004300.g004
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(Fig. 6D). Immunoprecipitation and phosphatase treatment
revealed that Whi5-WT was both hypo-phosphorylated and
hyper-phosphorylated in msn5D and swi6D cells similar to wild
type cells, indicating that the failure to export is not due to lack of
Whi5 CDK phosphorylation.
Whi5 C-terminal CDK sites affect cell size
To determine if the four C-terminal CDK sites of Whi5 affect
normal cell cycle progression, WHI5-WT and mutant alleles were
expressed from the WHI5 promoter in combination with SWI6-
SA4. In contrast to cells overexpressing Whi5-12Ala from the
GAL1 promoter (as in Fig. 4), cells expressing Whi5-12Ala and
Swi6-SA4 from their own promoters at physiologic levels are
viable and grow at rates similar to cells expressing Whi5-WT and
Swi6-WT (Fig. 7A) and have normal cell cycle profiles (data not
shown). When cells were synchronized in G1 with mating
pheromone and released, WHI5-12A SWI6-SA4 cells budded at
the same time and rate as WHI5-WT SWI6-WT cells (Fig. 7B).
Although the cells displayed no overt growth defect, WHI5-12Ala
SWI6-SA4 co-expressing cells were large (Fig. 7C). The mean cell
volume (fL) of cells co-expressing Whi5-12Ala and Swi6-SA4 was
67.6 fL, 40% larger than cells expressing wild type WHI5 and
SWI6 with a mean of 48.2 fL, indicating that phosphorylation of
either Swi6 or Whi5 is necessary for regulation of cell size. Cells
with WHI5-WT and SWI6-SA4, or cells with WHI5-12Ala SWI6-
Figure 5. Cellular localization of Whi5 phosphorylation mutants. (A) Cultures containing GAL1-WHI5-WT-GFP, (B) GAL1-WHI5-12Ala-GFP, (C)
GAL1-WHI5-4Ala-GFP, or (D) GAL1-WHI5-8Ala-GFP on a CEN plasmid were grown in galactose media and photographed for Whi5-GFP fluorescence in
unbudded and budded cells. Representative cells are shown. (E) Graph of Whi5 localization in budded cells, showing the percentage of budded cells
with cytoplasmic Whi5 in either wild type BY4741 or swi6D [SWI6-SA4] cells.
doi:10.1371/journal.pone.0004300.g005
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cells, demonstrating that the effect on cell size is not observed in
cells with either mutant alone. We also analyzed the cell size
distribution of Whi5 CDK mutants. When expressed with Swi6-
WT, Whi5-4Ala and Whi5-8Ala
1 cells were similar in size to
Whi5-WT and Whi5-12Ala (data not shown). In contrast, cells
expressing Swi6-SA4 with Whi5-4Ala (CDK sites 8, 9, 10, 12 Ala)
were larger in size, with a mean size of 62.0 fL, with a similar
distribution as Swi6-SA4 Whi5-12Ala cells (Fig. 7C). Conversely,
the size distribution of Swi6-SA4 cells with Whi5-8Ala
1 (CDK sites
8, 9, 10, 12 WT), with a mean size of 54.6, was similar to that of
cells containing both wild type alleles. These results demonstrate
that in combination with Swi6-SA4, phosphorylation of Whi5 C-
terminal CDK sites (8, 9, 10, and 12) is essential for maintenance
of cell size.
Discussion
Whi5 CDK and non-CDK phosphorylation
Whi5 is a negative regulator of G1 cell cycle progression that is
inactivated by CDK phosphorylation at Start [9,10]. Whi5
contains 12 putative CDK phosphorylation sites. However, it
has remained unclear if specific CDK phosphorylations sites on
Whi5 are utilized for inactivation or if a critical phosphorylation
threshold of randomly distributed CDK sites induces inactivation.
Here we found that Whi5 is phosphorylated in vivo on 10 CDK
sites and 6 novel, non-CDK sites. We also observed that Whi5 is
found hypo-phosphorylated at all stages of the cell cycle, including
early G1. We did not observe un-phosphorylated Whi5, even in
mating pheromone arrested cells. Five out of 6 of the non-CDK
sites are followed by acidic residues and conform to the consensus
sequences for casein kinase I or casein kinase II (CKA1/2) [39],
which is known to target transcription factors and RNA
polymerases [40]. We also found that hypo-phosphorylation is
not required for the repressive function Whi5 as whi5D cells
expressing Whi5-18Ala (all CDK and non-CDK sites mutated to
alanine) are normal in cell size and overexpression of Whi5-18Ala
causes lethality in cln3D cells. Further experiments are needed to
explore the biological function of Whi5 non-CDK phosphoryla-
tion and identify the kinase(s) responsible.
In addition to showing that Whi5 hypo-phosphorylation is not
essential for inhibitory function, this analysis shows that phos-
phorylation is neither essential for Whi5 inactivation nor passage
through Start. Whi5-12Ala expressed from the WHI5 promoter
fails to effect cell size distribution, indicating that the timing of cell
cycle entry is not significantly affected by the phosphorylation site
mutations. Our results differ from those of de Bruin et al, who
report that Whi5-7Ala expressed from the MET3 promoter caused
a measurable defect in cell cycle progression, with cells inducing
maximum SBF transcription at a ,10% larger cell size [10]. The
difference in results may be due to strain background differences
or the use of the heterologous promoter. Nevertheless, the
reported effect of Whi5-7Ala was not as significant as would be
predicted if Whi5 phosphorylation was essential for SBF
activation.
Redundancy of Whi5 and Swi6 Phosphorylation
In contrast to the finding that Whi5 phosphorylation is not
essential for cell size regulation at physiologic expression levels,
phosphorylation of Whi5 and Swi6 becomes essential when Whi5 is
overexpressed, as phosphomutants of these proteins synergize to
cause lethality. Swi6 has 5 putative CDK phosphorylation sites; four
of the five are in the N-terminal region, while the fifth CDK site is a
part of the ankyrin repeat domain of Swi6. The SWI6-SA4 mutant
created by Sidorova, et al., that contains mutations of the four N-
terminal CDK sites, does not affect periodic transcription of SBF
targets (data not shown) [16]. While Swi6-SA4 alone does not have a
significant cell cycle phenotype, Swi6-SA4 cells expressing GAL1-
WHI5-12Ala are inviable and arrest as large, elongated, unbudded
cells (data not shown) [9]. We exploited this phenotype in a
mutational analysis of Whi5 CDK sites to identify four C-terminal
CDK sites of Whi5, sites 8, 9, 10, and 12, that are necessary and
sufficient to prevent lethality when Whi5 is overexpressed in
combination with Swi6-SA4. Importantly, Whi5 retaining four or
more N-terminal CDK sites intact was not sufficient to prevent
lethality. This demonstrates that specific CDK sites of Whi5 are
required for inactivation, rather than simply a threshold number.
Consequently, we can exclude a model similar to that adopted for
proteins such as Sic1 that require a threshold number of CDK
phosphorylations to induce inactivation without a requirement for
specific sites of phosphorylation [41]. These four phosphorylated
residues of Whi5 may function to induce a conformational change or
otherwise influence the interaction between Whi5 and SBF
components. We conclude that phosphorylation of Whi5 and Swi6
is redundant, and that phosphorylation facilitates Whi5 inactivation.
CDK phosphorylation of Swi6 participates in the inactivation of
Swi6 by inducing cytoplasmic localization [16,18]. Swi6 Serine-
160 is adjacent to a nuclear localization sequence and inhibits
nuclear import once phosphorylated. When Ser-160 is mutated to
alanine, as it is in the Swi6-SA4 mutant, this results in constitutive
nuclear localization of Swi6 [16]. Whi5 is also exported from the
nucleus upon CDK phosphorylation and a C-terminal phosphor-
ylation mutant of Whi5 (sites 7–12 alanine) is largely nuclear [9].
Analysis of Whi5-GFP localization shows four C-terminal sites (8,
9, 10, and 12) are involved in nuclear export, as Whi5-4A was
unable to be completely exported to the cytoplasm in budded cells,
but are not sufficient to control localization, as Whi5-8Ala (8, 9,
10, and 12 wild type) remained nuclear in two thirds of budded
cells. This suggests that the four CDK sites implicated in Whi5
inactivation differ from the CDK sites required to induce Whi5
Figure 6. MSN5 is required for Whi5 nuclear export. (A) msn5D
cells, or (B) swi6D cells containing GAL1-WHI5-WT-GFP CEN plasmid were
grown in galactose media and photographed for Whi5-GFP fluores-
cence in unbudded and budded cells. Representative cells are shown.
(C) Cells expressing MSN5 from a GAL1 promoter integrated at the
endogenous locus contain either GAL1-WHI5-WT-GFP or GAL1-WHI5-
12Ala-GFP CEN plasmids. Cells were grown and photographed as above.
(D) Anti-Myc western blot of immunopurified Whi5-WT-13xMyc from
wild type cells, msn5D,o rswi6D cells untreated or treated with lambda
phosphatase. Arrows indicate presence of three different migrating
species.
doi:10.1371/journal.pone.0004300.g006
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in Whi5 export. These data also indicate that Whi5 dissociation
from SBF and its subsequent export to the cytoplasm are distinct
steps requiring phosphorylation of different CDK sites.
Despite the dramatic cell cycle phenotype of SWI6-SA4 cells
when Whi5-12Ala is overexpressed, CDK phosphorylation of
Whi5 and Swi6 is not essential for viability when Whi5 is
expressed at physiologic levels. Cells expressing both Swi6-SA4
Figure 7. Whi5 C-terminal CDK sites are required for maintenance of cell size. (A) Growth rates measured by OD600 of swi6Dwhi5D cells
expressing Swi6-WT or Swi6-SA4, and Whi5-WT or Whi5-12Ala from the 545 bp WHI5 promoter fragment on CEN plasmids. (B) Budding index of the
same strains as in A. Cells were synchronized with alpha factor and released into fresh media. Budded cells were counted every 10 minutes. (C) Cell
size distribution analysis wild type cells (BY4741), whi5D cells, and swi6D cells compared to swi6Dwhi5D cells expressing Swi6-WT or Swi6-SA4, and
Whi5-WT, Whi5-12Ala, Whi5-4Ala, or Whi5-8Ala from the 545 bp WHI5 promoter fragment on CEN plasmids.
doi:10.1371/journal.pone.0004300.g007
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completely viable, grow at normal rates, and enter the cell cycle
after mating pheromone induced G1 arrest with normal kinetics.
Their only apparent defect is a large cell size, suggesting that cells
are delayed in passing Start when Whi5 and Swi6 cannot be
phosphorylated. The four Whi5 CDK sites (8, 9, 10, and 12)
identified in the overexpression assay with Swi6-SA4 are also
necessary and sufficient to promote cell size regulation, as WHI5-
4Ala SWI6-SA4 cells were equivalent in size to WHI5-12Ala SWI6-
SA4 cells. Conversely, WHI5-8Ala
1 (CDK sites 8, 9, 10, and 12
wild type) cells were similar in size to WHI5-WT when combined
with SWI6-SA4. The effect of these mutants on cell size indicates
that the four specific CDK sites are important for the timing of
Whi5 inactivation, even at physiologic expression levels. However,
these data also imply that Whi5 and Swi6 are not essential targets
of Cln-Cdc28 for cell viability when expressed at physiologic
levels, and phosphorylation of Swi6 or the four sites of Whi5 is
only required for proper coordination of cell size with cell cycle
entry. In the absence of available CDK sites on Whi5 or Swi6,
cells must use a mechanism other than CDK phosphorylation to
activate SBF transcription. It is possible that the cell cycle activator
Bck2 plays a role under these conditions, given its ability to
activate SBF transcription independently of Cdc28 activity
[42,43].
Parallels between Whi5 and Rb
The pathway of transcriptional activation in yeast is functionally
similar to the mechanism of cell cycle entry in mammalian cells.
Whi5 is a functional analog of the Retinoblastoma tumor
suppressor protein that also represses transcription in early G1.
Previous studies from our laboratory show that Rb bound to E2F
transcription factors in early G1 is hypo-phosphorylated on CDK
phosphorylation sites [24]. Whi5 is similarly hypo-phosphorylated
in early G1, but hypo-phosphorylation is not necessary for its
repressive function. Further experiments are needed to determine
the requirement for Rb hypo-phosphorylation in repression of E2F
promoters. Additionally, phosphopeptide maps of hyper-phos-
phorylated Rb during late G1 are nearly identical to hypo-
phosphorylated Rb found in early G1 [44,45], indicating that
individual CDK sites are targeted equally in Rb phosphorylation
and suggesting specific sites do not have a significant function.
This suggests a model of Rb regulation where inactivation by
hyper-phosphorylation is achieved by phosphorylation of a
threshold number of CDK sites [28]. In contrast to that model
for Rb, we identified specific CDK sites that function in Whi5
inactivation and regulation of cell size. Because the regulatory
pathways of cell cycle entry are largely conserved between yeast
and mammalian cells, the mechanism of regulation by specific
phosphorylation observed for Whi5 suggests further investigation
of Rb phosphorylation in mammalian systems is warranted.
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